The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
ERWINASE (PPD Australia Pty Ltd)
Product name
ERWINASE
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
228 (255 working days)
Active ingredients
crisantaspase
Registration type
NCE/NBE
Indication
ERWINASE is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia (ALL) who have developed hypersensitivity to pegylated asparaginase obtained from E. coli.